Biosign Signs European Distribution Agreement

TORONTO, July 2, 2010 - Biosign Technologies Inc. (CNSX: BIO) today announced the signing of an
exclusive Master Distribution Agreement with Swiss-based DynamiCARE AG to
distribute the Biosign products in Switzerland, Germany, France, and Austria,
with an option to expand distribution throughout Europe. Under the terms of
the agreement, DynamiCARE will pay an initial fee of CDN $2.5 million, with a
commitment to achieve sales in excess of CDN $100 million in 2011.

The initial fee is payable upon UFIT(R) TEN-20 satisfying a market pilot
by the end of October 2010. The pilot will create immediate marketing
opportunities in selected markets while surveying key factors influencing
distribution and deployment decisions, such as support for high-volume usage,
multiple languages, and 'test-drives' by customers.

Biosign is set to deliver its products and services with Dell and Dell
Services on a global basis. Dell has been ranked first in customer service
and is arguably the largest healthcare IT company in the world, making them a
logical choice for our European product launch.

Patrick Dressel, President of DynamiCARE stated: "DynamiCARE focuses on
providing innovative solutions to diabetics. The UFIT(R) platform is the next
evolution of testing and diagnostics for personal medicine, promising a
momentous impact on diabetes monitoring in terms of cost, comfort, and
convenience. Our sales target reflects this promise."

UFIT(R) TEN-20 is an online medical device for self-monitoring of blood
pressure and blood glucose. The device takes the pulse at the wrist through
an inflatable cuff and gives blood pressure and blood glucose measurement
results. All measurements are indirect, noninvasive, and passive. The results
are stored on Biosign servers along with the test sample.

Radu Leca, President of Biosign noted: "Europe represents one third of
the global market. It outpaces the world in providing the best overall health
care, with France, Austria, Switzerland, and Germany as recognized global
leaders. We are pleased with the opportunity of using the cradle of modern
medicine to launch our radically unique product. In face of the magnitude of
the task, we will proceed prudently, harnessing DynamiCARE's presence in the
diabetes market and leveraging their channel partners to ensure a successful
launch."

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of common
health risks associated with blood pressure, glucose, and medication. The
core technology combines measurement, analysis, and rapid knowledge formation
to support health monitoring across global markets. The UFIT(R) medical
device technology powers quality data collection and analytics for clinical
diagnostics, self-care, wellness, disease state evaluation & management, and
remote patient monitoring. For more information on Biosign please visit
www.biosign.com.

About DynamiCARE AG

DynamiCARE is a dynamic company with its head office in Switzerland. The
emphasis of the company is in the supply of products to humans with diabetes.
The credo of DynamiCARE is to assure that people have access to affordable,
high quality and reliable diabetes care. Products include blood sugar
measuring instruments, insulin pen & needles, lancing devices, and innovative
products for wound management with nascent oxygen. For more information on
DynamiCARE please visit www.dynamicare.ch

About Dell Inc.

Dell Inc. (NASDAQ: DELL) listens to customers and delivers worldwide
innovative technology and business solutions they trust and value. Dell
Services develops and delivers a comprehensive suite of services and
solutions in applications, business process, consulting, infrastructure and
support to help customers succeed.

The CNSX has neither approved nor disapproved the contents of this press
release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1-(416)-218-9800 ext. 234, Email: ceo@biosign.com

For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: +1-(416)-218-9800 ext. 234, Email: ceo at biosign.com